UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`WATSON LABORATORIES, INC.
`Petitioner
`
`V.
`
`UNITED THERAPEUTICS,INC.
`Patent Owner
`
`Patent No. 9,339,507
`Issue Date: May 17, 2016
`Title: TREPROSTINIL ADMINISTRATION BY INHALATION
`
`Inter Partes Review No. 2017-01622
`
`
`DECLARATION OF DR. AARON WAXMAN
`
`seeeget
`
`UNITED THERAPEUTICS, EX. 2040
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 1 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`I, Dr. Aaron Waxman,hereby declare as follows:
`
`1.
`
`I am a pulmonary critical physician in Boston, Massachusetts.
`
`I am
`
`the Executive Director of the Center for Pulmonary and Heart Disease in the Heart
`
`and Vascular Center at Brigham and Women’s Hospital in Boston, Massachusetts.
`
`I am boardcertified in Internal Medicine, Pulmonary Disease, and Critical Care
`
`Medicine.
`
`I have been practicing as a pulmonary andcritical care doctor for over
`
`20 years.
`
`I am a memberof the American College of Chest Physicians, The
`
`American Thoracic Society, the Pulmonary Hypertension Association, and the
`
`Pulmonary Vascular Research Institute.
`
`De
`
`I am an Associate Professor of Medicine at Harvard Medical School
`
`and have dual appointments in the Pulmonary Critical Care and Cardiovascular
`
`Medicine divisions at the Brigham and Women’s Hospital. I have previously
`
`served as assistant professor in Medicine at the Yale University School of
`
`Medicine and Tufts University School of Medicine. I have authored or co-
`
`authored more than 100 peer-reviewed journalarticles, book chapters and reviews.
`
`3.
`
`I received my Bachelor’s degree from George Washington University.
`
`I received a Ph.D. in Anatomy and Neuroscience at the Albany Medical College,
`
`and an M.D. from Yale University School of Medicine.
`
`I completed my internship
`
`and residency in Internal Medicine at Yale New Haven Hospital. I also completed
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 2 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`a Fellowship in Pulmonary andCritical Care at the Yale School of Medicine. My
`
`curriculum vitae is provided as Exhibit 2041.
`
`4.
`
`I am a paid consultant for United Therapeutics, the assignee of U.S.
`
`Patent No. 9,339,507 (“the ’507 patent”), in connection with IPR2017-01622. My
`
`compensation does not depend on the content of my opinionsorthe disposition of
`
`this proceeding.
`
`I have been retained by United Therapeutics to provide technical
`
`expertise and my expert opinion on the °507 patent.
`
`5.
`
`While I am neither a patent lawyer nor an expert in patent law, I have
`
`been informed of the applicable legal standards for obviousnessofpatent claims.
`
`I
`
`understand that the Petition brought forward by Watson Laboratories, Inc.
`
`(“‘Petitioner” or “Watson’”) challenges claims 1-9 of the *507 patent.
`
`6.
`
`For reference, below is a list of the Exhibits that are cited herein:
`
`Exhibit No.
`1001 U.S. Patent No. 9,339,507
`1002
`Declaration of Dr. Maureen Donovan
`Robert Voswinckel,et al. “Inhaled treprostinil sodium for the
`treatment of pulmonary hypertension” Abstract #1414, Circulation,
`110, 17, Supplement
`(Oct. 2004): III-295
`
`1003
`
`1004
`
`WO 93/00951 1013
`
`Hossein Ardeschir Ghofrani, Robert Voswinckel, et al., “Neue
`Therapieoptionen in der Behandlung der pulmonalarteriellen
`1005
`Hypertonie,” Herz, 30,4 (June 2005): 296-302
`1012
`
`Declaration of Dr. Scott Bennett
`1028 Olschewski H., et al., Aerosolized Prostacyclin and Iloprostin
`
`
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 3 of 48
`
`3
`
`

`

`
`
`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`
`
`1046
`
`Severe Pulmonary Hypertension, 1996 Ann. Intern. Med. 124(9),
`
`820-824 (1996)
`Olschewski, et al., Pharmacodynamics and Pharmacokinetics of
`Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe
`1029
`Pulmonary Hypertension, Chest J., 124(4), 1294-1304 (Oct. 2003)
`
`Voswinckel, R., et al., “Inhaled treprostinil is a potent pulmonary
`vasodilator in severe pulmonary hypertension,” 25 European Heart
`Journal 22, 218 (2004
`Substantive Submission filed in 12/591,200 (Nov. 9, 2015) (with
`accompanying Declaration of Dr. Roham T. Zamanian)
`Amendment and Replyfiled in 12/591,200 (Feb. 2, 2016) (with
`ing
`Second Declaration of Dr. Roham T. Zamanian
`
`1162
`
`1163
`
`2002
`
`
`2003
`Newman,Stephen P. Respiratory drug delivery: essential theory and
`practice. Respiratory Drug Delivery Online, 2009 (excerpt).
`004
`Hill, N., Therapeutic Optionsfor the Treatment ofPulmonary
`Hypertension, Medscape Pulmonary Medicine 9(2) (2005).
`Exhibits Accompanying First Declaration of Dr. Roham Zamanian
`and Amendment and Reply filed in 12/591,200 (Nov.9, 2015) (Ex.
`
`2005
`
`2012
`2020
`
`
`
`
`
`
`2021
`
`2023
`Curriculum vitae of Dr. Lewis Rubin
`7024
`2002 Press Release Regarding Promotion of Robert Roscingo
`(accessed October 10, 2017)
`Shield Therapeutics Biography for Carl Sterritt (accessed October
`10, 2017)
`Listing of Issues and Supplements of Circulation Accessible on
`Circulation Website (accessed April 17, 2018
`
`2041
`Curriculum vitae of Dr. Aaron Waxman
`2042
`Mosby’s Medical Dictionary. 7" ed. Mosby Elsevier, 2006 (excerpt).
`Leung, K, Louca E., & Coates, A. “Comparison of Breath-Enhanced
`to Breath-Actuated Nebulizers for Rate, Consistency, and
`i
`,” Chest, 126(5):1619-1627 (2004
`Rau, J.L., “Design Principles of Liquid Nebulization Devices
`Currently in Use,” Respir. Care, 47(11):1257-1275 (2002
`Atkins, P.J. & T.M. Crowder. “The Design and Development of
`
`2025
`
`2037
`
`2043
`
`2044
`
`2045
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 4 of 48
`
`4
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`
`
`Inhalation Drug Delivery Systems,” Pharmaceutical Inhalation
`Aerosol Technology, 2nd Ed. (A.J. Hichey ed., CRC Press), Ch. 9
`2003
`Ventavis® Patient Brochure
`Rau, J.L. Respiratory Care Pharmacology. 6" Ed. Mosby, 2002
`
`excerpt
`
`
`
`2046
`3047
`
`I.
`
`BACKGROUND
`
`7.
`
`At the time ofthe invention, as today, pulmonary hypertension was a
`
`poorly understood, often fatal, disease with limited treatment options. Prior
`
`treatments of pulmonary hypertension with a prostacyclin analog included
`
`epoprostenol, which had significant burdens and challengesto patients.
`
`Epoprostenol can only be administered intravenously. Ex. 2004. The need for a
`
`permanenttranscutaneousintravenous catheter to administer epoprostenol posed
`
`risks of infection and sepsis. Jd. Epoprostenol patients also risk sudden occlusion
`
`of the catheter which can precipitate hemodynamiccollapse because of the several
`
`minute half-life of the drug.
`
`/d. Moreover, epoprostenol requires daily mixing and
`
`refrigeration, thus, requiring the patient to carry a cold pack to avoid degradationat
`
`room temperature and an infusion pumpto safely administer the drug.
`
`8.
`
`Because of these drawbacks, epoprostenolis not suitable for treating
`
`all patients. Indeed, there are a numberof patients for whom intravenous therapy
`
`is not suitable. For example, for pulmonary hypertension patients with lung
`
`disease, it is critical to maintain matchedventilation and perfusion to optimize
`4832-0937-8914.1
`°
`UNITED THERAPEUTICS, EX. 2040
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 5 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`oxygenation and the excretion of carbon dioxide from the lung. Whena patient
`
`suffers from lung disease (e.g. pneumonia, emphysema,or interstitial lung
`
`diseases), the lung automatically diverts blood flow away from diseased areas of
`
`the lung and toward the non-diseased portions — optimizing lung function. Since
`
`intravenous delivery of a vasodilator results in indiscriminate vasodilation, this
`
`optimization is disrupted by intravenous delivery. Similar drawbacksexist with
`
`intravenous and subcutaneoustreprostinil.
`
`9,
`
`In addition, in my clinical experience, I have found that patients prefer
`
`inhaled treatment becauseit is less intrusive (i.e. doesn’t require constant infusions
`
`or a Hickman catheter) and also has less systemic side effects. The preference for
`
`inhaled treatment over intravenous administration is about 2 or 3 to 1. Thus, asa
`
`clinician considering what drug to administer a pulmonary hypertension patient,I
`
`would not compare intravenoustherapeutics to inhaled therapeutics. Rather, the
`
`relevant comparison for a patient who either cannot support intravenous
`
`administration or has requested inhaled administration would be which of the two
`
`inhaled pulmonary hypertension products — Tyvaso ® or Ventavis ® - would be
`
`suitable for treatment.
`
`10.
`
`Prior to May 15, 2006, the only FDA-approved prostacyclin-type drug
`
`that could be given in an inhalable form wasiloprost, marketed as Ventavis ®. At
`
`that time, the results of an Aerosol Iloprost Randomized (AIR) Study documenting
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`6
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 6 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`the effects of inhaled iloprost had been public for about three-and-a-half years, and
`
`Ventavis ® had been on the market for about one-and-a-half years. Ex. 1162, 21;
`
`Ex. 2005, 1-28. As Dr. Zamanian noted in his Declaration of May 15, 2016,
`
`clinicians were concernedthat the adoption of Ventavis® was happening too
`
`rapidly and werestill largely of the opinion that intravenous administration of a
`
`prostacyclin analog was preferable to inhaled delivery. Ex. 1162, 21.
`
`Surprisingly, even in view of these concerns, when Tyvaso ® entered the market in
`
`2009, there wasa rapid shift from Ventavis ® to Tyvaso ®. See Ex. 1162, 19-39;
`
`Ex. 1163, 23-28.
`
`II.
`
`CLAIMS OF THE ’507 PATENT
`
`11.
`
`Ihave reviewed the claims of the ’507 patent. Provided below for
`
`reference is the language of claim | of the ’507 patent:
`
`A kit for treating pulmonary hypertension comprising:
`
`a formulation comprising 200 to 1000 g/mlof treprostinil or a
`
`pharmaceutically acceptable salt thereof;
`
`a pulsed ultrasonic nebulizer comprising an opto-acoustical
`
`trigger configured to (a) aerosolize a fixed amountoftreprostinil per
`
`pulse, and (b) deliver by inhalation a therapeutically effective single
`
`event dose of said formulation,
`
`said single event dose comprising from 15 pg to 90 ug of
`
`treprostinil or a pharmaceutically acceptable salt thereof delivered in 1
`
`to 18 breaths; and
`
`4832-0937-8914.1
`
`instructions for using the pulsed ultrasonic nebulizer with the
`7
`UNITED THERAPEUTICS, EX. 2040
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 7 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`formulation to treat a patient with pulmonary hypertension by
`
`delivering 15 ug to 90 ug treprostinil or a pharmaceutically acceptable
`
`salt thereof in 1 to 18 breaths to the patient in the single event dose.
`
`Ex. 1001, col. 18:12-28.
`
`I understandthat this claim is an “independentclaim” and
`
`that all subsequentclaims, i.e. claims 2-9, depend from this claim — meaning that
`
`claims 2-9 require the same features or “limitations” as claim 1 but also include
`
`additional limitations. Ex. 1001, col. 18:29-52.
`
`12.
`
`[have been informed that the terms found in the claimsof a patent
`
`must be given their broadest reasonable interpretation consistent with the body
`
`text, or “specification,” of the patent at issue and the statements made during
`
`prosecution of the patent, or “prosecution history,” as it would be interpreted by
`
`one of ordinary skill in the art. Therefore, in this section, I provide my opinions on
`
`how a person ofordinary skill in the art (““POSA”) would understand certain claim
`
`terms.
`
`A.
`
`Person of Ordinary Skill in the Art
`
`13.
`
`[am informed by counselthat a patent is to be interpreted from the
`
`perspective of a hypothetical person referred to as the person of ordinary skill in
`
`the art (which I will often refer to as a “POSA”) to which the patent pertains.
`
`I am
`
`further informed that a determination of the level of ordinary skill is based on,
`
`amongotherthings, the type of problems encounteredin the art, prior art solutions
`4832-0937-8914.1
`8
`UNITED THERAPEUTICS, EX. 2040
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 8 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`to those problems, rapidity with which innovations are made, sophistication of the
`
`art, and the educational level of active workersin thefield.
`
`14.
`
`The claimsof the ’507 patent are directed to a kit for “treating
`
`pulmonary hypertension” with a specific “pulsed ultrasonic nebulizer.” Ex. 1001,
`
`col. 18:12-52.
`
`I understand that several of the inventors listed on the ’507 patent
`
`have post-graduate degrees in the field of medicine or drug developmentandall
`
`had at least several years of research, executive, and/or clinical experience in the
`
`investigation and treatment of pulmonary hypertension and in developing
`
`pharmaceutical products for the treatment of pulmonary hypertension. Ex. 2020,
`
`41, 7; Ex. 1028, 1; Ex. 1029, 1; Ex. 2023; Ex. 2024; Ex. 2025.
`
`15.
`
`Consistent with the experience of the named inventors,it is my
`
`opinion that a POSAatthe time of invention would have been a person with a
`
`post-graduate degree in medicine or drug development(such as the pharmaceutical
`
`sciences) with at least two years of experience in the investigation or treatment of
`
`pulmonary hypertension. A POSA mayalso have had additional experience in the
`
`study, development, or use of dosage forms that had been usedto treat pulmonary
`
`hypertension, such assolid oral dosage forms(e.g., tablets and capsules),
`
`injectables, and inhaled therapies. A POSA mayhavehad a lowerlevel of formal
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`7
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 9 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`education if such a person had more years of experience in the investigation or
`
`treatment of pulmonary hypertension.
`
`16.
`
`I understand the Petitioner and its expert Dr. Donovan have offered a
`
`different interpretation of a POSA. Ex. 1002, 974. Even if this definition is
`
`applied, it would not affect my ultimate conclusions regarding the ’507 patent
`
`discussed herein.
`
`B.
`
`“pulsed” and “pulse”
`
`17.
`
`Both the terms “pulse” and “pulsed” are found in claim 1. Ex. 1001,
`
`col. 18:12-28. The term “pulsed” is used as the adjective form of the word
`
`“pulse.”
`
`18.
`
`A POSA would understand the plain meaning of the term “pulse.”
`
`For example, the Oxford Dictionary of English provides the following definition of
`
`the word “pulse”: “[a] single vibration or short burst of sound, electric current,
`
`light, or other wave.” Ex. 2002, 3. The same dictionary defines the word “wave”
`
`in the physics context as “a periodic disturbance ofthe particles of a substance
`
`which may be propagated without net movementofthe particles, such as in the
`
`passage of undulating motion, heat, or sound.” Ex. 2002, 5. A POSA would
`
`accept both dictionary definitions as providing the plain meaning of the terms
`
`“pulse” and “wave.” In the scientific and medical context “pulse”is also
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`10
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 10 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`understoodto refer to rhythmic and periodic waves. See, e.g., Ex. 2042, 4
`
`(defining “pulse” as “a brief electromagnetic wave”and “a rhythmic beating or
`
`vibrating movement”; defining “pulsed Doppler”as “a type of Doppler device
`
`involving the transmission of a short-duration burst of sound into the region to be
`
`examined”; and defining “pulsed laser” as “a laser that emits short bursts of energy
`
`at fixed intervals rather than a continuousstream of energy’). In the same way,in
`
`the context of “pulsed nebulizers,” pulsed has long cometo be understood as
`
`meaningshort periods of nebulization at fixed intervals, rather than continuous
`
`nebulization. Ex. 2043 (distinguishing pulsed nebulization versus continuous
`
`nebulization).
`
`19.
`
`Inthe specification of the ’507 patent, the term “pulse”is used to refer
`
`to the intermittent and periodic delivery of aerosol for a fixed duration, followed
`
`by pauses of a fixed duration in cycles. Ex. 1001, col. 14:36-39. For example, the
`
`specification identifies that “[a] pulse of aerosol was generated every 6 seconds”
`
`and that the pulsed ultrasonic nebulizer generated aerosol “in cycles consisting of 2
`
`seconds aerosol production (pulse) and 4 seconds pause.” Ex. 1001, col. 4:41-42;
`
`col. 14:36-39.
`
`20.
`
`Inthe claims, each “pulse” is meant to correspond with eachbreath.
`
`Ex. 1001, col. 18:12-28. A similar interpretation of the term is found in Exhibit
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`i
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 11 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`1163, which I understand to be documents and a declaration submitted during the
`
`prosecution of U.S. Patent No. 9,358,240 (“the ’240 patent’’), where it says a
`
`“pulsed”ultrasonic nebulizer produces“a ‘pulse’ of aerosol production followed
`
`by a pause”andthat the generated pulses are “spaced apart in time that correspond
`
`to each breath inhaled by a human.” Ex. 1163, 12-13.
`
`I understandthat “the ’240
`
`patent has the samespecification as the ’507 patent and also uses the term “pulsed”
`
`in the claims.
`
`I have also been informedthat, since the ’240 patent is “related” to
`
`the *507 patent, statements submitted in prosecution of the ’240 patent are relevant
`
`to the interpretation of the claims of the ’507 patent. Ex. 1001, 1(60).
`
`21.
`
`Based on the specification and the ’240 prosecutionhistory,it is
`
`apparentthat the term pulse in the claimsrefers to a short burst of aerosol
`
`production. Further, the specification and prosecution are consistent with the
`
`meaning of both pulse and wavein that the pulse of aerosol must occur with a
`
`specified periodicity: in other words, a wave form with consistent time intervals
`
`between each pulse.
`
`22.
`
`In view ofthe plain meaning, specification, and prosecution history, a
`
`POSA would understand the term “pulse”to refer to a period of aerosol generation
`
`and the term “pulsed”to refer to the generation of such pulses with a specified
`
`periodicity, or fixed interval.
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`12
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 12 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`C. “opto-acoustical trigger which allows said patient to synchronize
`
`each breath to each pulse”
`
`23.
`
`Ihave been informed that United Therapeutics and Watson reached an
`
`agreementinarelatedlitigation that the phrase “an opto-acousticaltrigger”in
`
`claim 1 means “a trigger with an optical element(e.g., light) and an acoustical
`
`element(e.g., sound).” I also understand that this agreementapplies to this
`
`proceeding as well.
`
`24.
`
`The definition above provides examples of both the optical and
`
`acoustical elements of the “opto-acoustical trigger” but no definition for the word
`
`“trigger” is provided. Therefore, a POSA would understand the word “trigger” in
`
`this phrase according its plain meaning. The Oxford Dictionary of English defines
`
`“trigger” as “an event that is the cause of a particular action, process, or situation.”
`
`Ex. 2002, 4. Thus, an “opto-acoustical trigger” would be understood to require an
`
`optical element(e.g., light) and an acoustical element(e.g., sound) that is designed
`
`to cause a particular action, process, or situation.
`
`25.
`
`The specification of the 507 patent describes the “opto-acoustical
`
`trigger” as synchronizing inhalation to pulses. Ex. 1001, col. 14:39-41. Therefore,
`
`in view of the plain meaning of the word andthe specification, a POSA would
`
`understandthe optical element(e.g., light) and the acoustical element(e.g., sound)
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`Is
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 13 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`are designed to “cause the particular action, process, or situation” of the
`
`synchronization of the patient’s inhalation with each pulse. This synchronization
`
`of the patient’s breathing to the device contrasts the claimed pulsed ultrasonic
`
`nebulizer from other kinds of pulsed ultrasonic nebulizers, such as a breath-
`
`actuated pulsed ultrasonic nebulizer where the device adapts the pulse to the
`
`patient’s individual breathing pattern, allowing the patient to control length of
`
`pulse and spacing between pulses.
`
`26.
`
`The claimed “opto-acoustical trigger”is different from the
`
`combination of an optical element and an acoustical element. The “opto-acoustical
`
`trigger” is designed to cause a human to immediately inhale each aerosol pulse
`
`from the pulsed ultrasonic nebulizeras it is generated and to “synchronize the
`
`inspiration to the end ofthe aerosol pulse, thereby providing exact dosage.” Ex.
`
`1001, col. 14:40-41. A combination of an optical element and an acoustical
`
`element that simply provides information, such asa signalor an alert, cannot be
`
`considered an “opto-acoustical trigger” without evidencethatit is designed to
`
`cause immediate inhalation of individual aerosol pulses, as is used in this patent.
`
`D. “single event dose”
`
`27.
`
`Claim 1 also refers to a “single event dose” and requires that 15 to 90
`
`microgramsof treprostinil or its salt be delivered in 1 to 18 breaths to the
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`M4
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 14 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`pulmonary hypertension patient in a “single event dose.” Ex. 1001, col.18:19-23.
`
`I further note that the patent specification gives the following supporting
`
`explanation of this term:
`
`Administering of treprostinil in a single event can be carried out in a
`
`limited numberofbreaths by a patient....
`
`Thetotal time of a single administering event can beless than 5
`
`minutes, or less than 1 minute, or less than 30 seconds.
`
`Treprostinil can be administered a single time per day or several times
`
`per day.
`
`Ex. 1001, col. 7:54-62. The patent specification also presents results showing that
`
`an inhaled dose of 15 micrograms “induced pulmonary vasodilation for longer than
`
`3 hours compared to placebo inhalation.” Ex. 1001, col. 17:39-44. Claims 3 and 9
`
`further indicate that the patient is instructed “not to repeat the single event dose for
`
`a period of at least 3 hours.” Ex. 1001, col. 18:32-34, 50-52. Based on how
`
`“single event dose”is used in the patent, a POSA would understand it to mean the
`
`total time during which the pulmonary hypertension patient inhales a necessary
`
`dose of treprostinil in one sitting, which may be spaced apart from the next single
`
`event dose by several hours, and there may be more than one pulse and more than
`
`one breath corresponding to each pulse within a single event dose.
`
`Il.
`
`INSTITUTED GROUND1
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`IS
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 15 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`28.
`
`I have been informedthat in order for a patent claim to be considered
`
`obvious, each and every limitation of the claim must be present within the priorart
`
`or within the prior art in combination with the general knowledge held by a POSA
`
`at the time an invention was made, and that such a person would havea reason for
`
`and reasonable expectation of success in combining these teachings to achieve the
`
`claimed invention.
`
`I understand there may bea variety of rationales that can
`
`demonstrate the reason for and reasonable expectation of success in combining
`
`selected teachings, but, regardless of the rationale used, it must be supported by
`
`evidence.
`
`29.
`
`I understand the Board is reviewing whether claims 1-9 are obvious
`
`over the references provided in “Ground 1”noted below.
`
` Ground
`Ground 1
`
`References
`
`Robert Voswinckel,et al. “Inhaled treprostinil
`
`sodium for the treatment of pulmonary
`
`hypertension” Abstract #1414, Circulation, 110, 17,
`
`Supplement (Oct. 2004): III-295 (“Voswinckel,”
`
`Ex. 1003)
`
`U.S. Patent Application Publication No.
`
`2004/0265238 (“Chaudry,” Ex. 1004)
`
`Hossein Ardeschir Ghofrani, Robert Voswinckel, et
`
`al., “Neue Therapieoptionen in der Behandlung der
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`‘6
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 16 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`
`
`pulmonalarteriellen Hypertonie,” Herz, 30,4 (June
`
`2005): 296-302 (“Ghofrani,” Ex. 1005)
`
`
`I further understand the Board hasrelied on both the references cited under
`
`“Ground 1” and Dr. Donovan’s declaration (Ex. 1002) in its decision to “institute
`
`trial” on this ground. In this section, I provide my opinions on Voswinckel(Ex.
`
`1003), Chaudry (Ex. 1004), Ghofrani (Ex. 1005), and Patton (Ex. 1012) in relation
`
`to the Board’s decision, Watson’s arguments, and the supporting testimony
`
`provided in Dr. Donovan’s declaration.
`
`A. Voswinckel
`
`30.
`
`Dr. Donovan’s reliance on Voswinckel for showing the “safety,
`
`tolerability, and clinical efficacy” of inhaled treprostinil (Ex. 1002, 978) is
`
`inconsistent with how a POSA wouldinterpret Voswinckel’s findings andis
`
`premised on a fundamental misunderstanding of Voswinckel.
`
`.
`
`31. While the authors do state they are interested in evaluating the safety,
`
`tolerability and clinical efficacy in patients, they fail to disclose any information
`
`about the amountof drug per breath or spacing of breaths within an inhalation
`
`event, and the conclusions actually reflected a far more cautious conclusion. The
`
`conclusion expressly addresses efficacy only in the context of single acute dosing
`
`and only of a single measure of pulmonary hemodynamics—this cannotlead to a
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`iM
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 17 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`conclusion ofclinical efficacy. Ex. 1003, 7. At best, the authors suggest long term
`
`treatment (based on 2 compassionate use patients) is “promising” and agree the
`
`results “warrant controlled studies investigating this approachin a larger series of
`
`patients.” Jd.. This invitation to investigate further is hardly the demonstration of
`
`effective and safe treatment Dr. Donovan claims.
`
`32.
`
`Voswinckelis a single-paragraph conference abstract, meaning that
`
`(1) it is not edited by a peer review panel of editors but published as-submitted
`
`following a less-stringent grading and acceptancecriteria than scientific
`
`manuscripts and (2) it is not meant to be a definitive work. Ex. 1003, 1-7. Rather,
`
`such abstracts are generally submitted by researchers looking to provide their
`
`administration with a reason they should attend the meeting. To POSAs, these
`
`abstracts are not considered publications per se. In fact, at Harvard, my colleagues
`
`and I are required to remove anabstract from our CVsif it has not resulted in a
`
`publication within three years. This happens quite often since conference abstracts
`
`reflect preliminary data and hypotheses which often end up being contradicted by
`
`full studies. A POSA would not rely on such preliminary data to conclude that a
`
`drug of any kind wassafe, tolerable, or clinically efficacious.
`
`33.
`
`To the extent that Voswinckel reports “promising” results with
`
`inhaled treprostinil, a POSA would view this with a degree of skepticism. A
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`18
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 18 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`reader would review the abstract results for what they actually show.
`
`It is a huge
`
`leap for Dr. Donovanto concludesafety and efficacy from such a conference
`
`abstract that only purports to be “promising” for long-term potential — a leap a
`
`POSA would nottake.
`
`34. Atbest, Voswinckelsets out a study to assess “the effects of inhaled
`
`TRE[treprostinil] on pulmonary hemodynamicsand gas exchange in severe
`
`pulmonary hypertension.” Ex. 1003, 7. Nocriticality is attributed to the type of
`
`device used noris any clarification given on how the device is used or whatactual
`
`dose (in ug ) is delivered. Jd. The dose and device in Voswinckelare incidental.
`
`Id.
`
`It is also unclear from Voswinckel what inhalation regimen wasusedfor the
`
`two “compassionate treatment” patients and whetherthey are a subset of or a
`
`separate population from the 17 patients treated with 3 single breaths of the 600
`
`ug/mLsolution, with no information on how muchdrug was delivered within each
`
`breath or how the breaths were spaced apart. Jd. The only clear teaching is that
`
`the two “compassionate treatment” patients were given four inhalations of
`
`treprostinil per day. Jd. A POSA would not know whatdose, concentration, or
`
`device was used to deliver the “compassionate treatment” based on the scant
`
`information provided. A POSA would also be cautious of results gleaned from a
`
`two-patient, uncontrolled sample size, particularly where those patients are
`
`“compassionate use”treatment.
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`19
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 19 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`35.
`
`Ihave been informed that in order for Voswinckel to be considered
`
`“prior art,” for the purposesof this proceeding, it must have been “publicly
`
`accessible” and that the legal standard for accessibility was whether Voswinckel
`
`was disseminated or otherwise made available to the extent that a POSA exercising
`
`reasonable diligence can locate it. Based on this legal standard, it is my opinion
`
`that Voswinckel wasnot publicly accessible.
`
`36.
`
`A POSAlooking for information on treatment of pulmonary
`
`hypertension with treprostinil on or before May 15, 2006 would typically do most
`
`of his or her research online. The primary resource for online searchingin the field
`
`is PubMed. A POSAtypically searches PubMedusinga string of search terms,
`
`whichcould include the disease (e.g. “pulmonary hypertension”or “pulmonary
`
`arterial hypertension’) and/or the active agentof interest (e.g., “prostacyclin-
`
`analog”or “treprostinil”). In circumstances where a POSAis already aware of the
`
`workof a set of authors orinstitution, a search of PubMed of those terms might
`
`also be employed.
`
`37.
`
`There is no PubMedentry for Voswinckelat all, much less one keyed
`
`to the authors, their institution, pulmonary hypertension,or treprostinil.
`
`Conference abstracts, like Voswinckel, are not usually indexed on PubMed
`
`because, as noted above, they are not considered peer-reviewed to the same extent
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`20
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 20 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`as a journal publication. Therefore, a POSA exercising reasonable diligence would
`
`not have beenable to locate it in the most typical and helpful way employed by a
`
`POSA.
`
`38.
`
`In the unlikely event that no relevant resources were pulled up on
`
`PubMed, a POSA mightturn to a library to locate books and peer-reviewed
`
`journals (in print) that are relevant to pulmonary hypertension. Typically, peer-
`
`reviewed journals are about 100 pages and contain an index ortable of contents.
`
`39.
`
`Fora POSAto find Voswinckelthrough either of these methodsis
`
`akin to finding a needle in a haystack. Voswinckelis one of over 1,000 abstracts
`
`in a supplementto Circulation providing all the abstracts for the American Heart
`
`Association’s 2004 Scientific Sessions in advance of the conference; the
`
`supplementis over 1,000 pages (an order of magnitude longer than a peer-
`
`reviewed journal). Ex. 1003, 4, 7. The version provided by Watson does not even
`
`contain a table of contents showing how the supplement is organized and/orifit
`
`could be searched. Ex. 1003.
`
`40.
`
`lI understand that Watson hasrelied on Dr. Bennett for the evidence
`
`that Voswinckel was publicly available. I have reviewed Dr. Bennett’s declaration
`
`(Ex. 1013) and disagree with him that Voswinckel was publicly accessible.
`
`Importantly, he concludes only that “in [his] opinion, Circulation and its abstract
`
`4832-0937-8914.1
`
`UNITED THERAPEUTICS, EX. 2040
`71
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 21 of 48
`
`

`

`IPR2017-01622
`
`Declaration of Dr. Aaron Waxman
`
`supplements were sufficiently accessible to the public interested in the art; and an
`
`ordinarily skilled researcher, exercising reasonable diligence, would have had no
`
`difficulty finding copies of Circulation and its abstract supplements.” Ex. 1013,
`
`430. But the question is not whether a POSA could find Circulation orits
`
`sup